Exemption from the exit tax may be available in respect of a range of assets which remain (post exit) within the charge to ...

As the industry advances, pharmaceutical companies must address a critical ... In Q1 2024 alone, biotech start-ups raised a combined $2.9 billion, and the demand is only expected to increase.

Teva Pharmaceutical ( TEVA -1.08%) is my worst-performing stock so far in 2025, down 27% in less than three months as of this ...

President Donald Trump is expected to impose tariffs on $7 billion worth of Australian farm produce which enters the US.

Most people start businesses to make more money. Mark Cuban? He's already got the billionaire badge. Now he's out to prove that capitalism doesn't have to be cutthroat. Speaking at WIRED's The Big ...

The details of a new raft of tariffs, set to be announced by the US president on Wednesday, are still largely unknown.

“Discounts would start at around 35 to 40 per cent and rise according to volume,” she says. Much like any other small business, you will probably want to save costs in your early stages by not ...

The Trump tariffs — aimed at boosting U.S. jobs and tax revenues — will also affect imported auto parts, which were valued ...

Founders who are about to take the leap to acquire another company need to be prepared for what's ahead, says Dr. Anas Nader, ...

Pay too much in royalties and you eat up potential ... New royalty approaches Pharmaceutical and biotechnology companies today use varying techniques to negotiate and set royalty rates.

While officials still expect potential cut rates twice in 2025, there is growing uncertainty about when and how much borrowing costs ... bring some relief. At Business Insider, we keep track ...